XBI (Biotech) Stock Analysis - Analyst Ratings

Biotech (XBI) is a publicly traded the market company. As of May 20, 2026, XBI trades at $131.56 with a market cap of $0 and a P/E ratio of 0.00. XBI moved +3.92% today. Year to date, XBI is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces XBI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate XBI?

The average price target is $0.00.

XBI Key Metrics

Key financial metrics for XBI
MetricValue
Price$131.56
Market Cap$0
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$0.00
52-Week Low$0.00
Volume10.38M
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

XBI Analyst Consensus

XBI analyst coverage data. Average price target: $0.00.

Latest XBI News

Common questions about XBI

What do analysts rate XBI?
The average price target is $0.00.
Does Rallies show XBI price targets?
Yes. Rallies tracks XBI analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is XBI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XBI. It does not provide personalized investment advice.
XBI

Biotech